Immune-boosting combo aims to wipe out rectal cancer before surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years and ≤75 years on the day of signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 3. Histologically proven rectal adenocarcinoma. 4. \<12 cm from anal verge. 5. Clinical stage of T3/T4 or N positive and M0 6. No previous chemotherapy, radiotherapy, immunotherapy or surgical treatment 7. No immune system disease (e. g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic vasculitis, scleroderma, mixed connective tissue disease, dermatomyositis (DM), hyperthyroidism, hypothyroidism, ulcerative colitis (UC), autoimmune hemolytic anemia (AIHA) or human immunodeficiency virus (HIV) infection. 8. Adequate hepatic and renal function to chemoradiotherapy, immunotherapy and surgery. 9. Willing and able to provide written informed consent. Exclusion Criteria: 1. Allergic to any component of chemotherapy or immunotherapy; 2. Patients with multiple primary colorectal cancer; 3. Other malignant tumors within 5 years, except for adequately treated cervical carcinoma in situ or cutaneous basal cell carcinoma, or basically controlled localized prostate cancer or surgically excised ductal carcinoma in situ of breast; 4. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, or other conditions requiring emergency surgical resection; 5. Prior or planed organ/bone marrow transplant 6. Patients who receive systemic steroid therapy or immunosuppressive agents within 30 days before enrollment in the study; 7. Pregnant or lactating women 8. Patients with a history of severe mental illness or being unable to comply with the research protocols. 9. Patients who have contraindications to chemoradiotherapy, immunotherapy or surgery. 10. Patients who have any other conditions that investigator judges unsuitable to participate.